key: cord-0909207-nn1eovd3
authors: Silini, Antonietta R.; Ponsaerts, Peter; Parolini, Ornella
title: Editorial: Perinatal Derivatives and the Road to Clinical Translation, Volume I
date: 2021-08-11
journal: Front Bioeng Biotechnol
DOI: 10.3389/fbioe.2021.741156
sha: 76d91a6b5e3ca793c5329997cb9c34d01dfa5448
doc_id: 909207
cord_uid: nn1eovd3

nan

Ranieri Cancedda, Independent Researcher, Genova, Italy studies and eventual translation of fetal membranes and their derivatives as antimicrobial agents from bench to bedside. These include the standardization of hACM, hAM and hCM preparation, standardization of the antimicrobial susceptibility testing methods, and designation of donor criteria that enable the optimal donor selection. Strengthening a consensus approach, a detailed characterization of PnD is of utmost importance for the comparison of results in order to determine PnD efficacy in preclinical studies. Tehrani et al. describe biological features of the amniotic membrane and potential modifications in addition to the required processes for sterilization and preservation, such as combination with gels and other composites, and the preparation of amniotic membrane extract to tailor its use in regenerative medicine applications. In addition, Weidinger et al. break down the amniotic membrane into its different anatomical sub-regions and their properties such as morphology, structure, and content/release of certain bioactive factors. They discuss the relevance of these different properties for tissue regeneration, altogether helping in the optimization and fine-tuning of the clinical applications of the amniotic membrane.

The COST SPRINT Action also aims to review studies in animal models in order to grade efficacy of therapeutic interventions and identify research gaps for the disease of interest. Ultimately, understanding the therapeutic potential and underlying biological mechanisms will allow for the identification of which PnD could potentially provide the optimal results in specific diseases. In this issue, a particular focus has been made on the amniotic membrane. As a matter of fact, several groups discuss the application of the amniotic membrane in wound healing, one of it's most advanced applications. Ruiz-Cañada et al. dissect the effects of the amniotic membrane on keratinocyte migration, proliferation and on the TGF-β signaling pathway and how this contributes to chronic wound healing. Vonbrunn et al. investigate the suitability of different scaffolds with amniotic membrane-derived mesenchymal stromal cells in vitro and in vivo, demonstrating potential new therapeutic approaches to wound care. Janev et al. instead explore the multi-targeted anticancer activity of the homogenate of ammiotic membrane by reporting its effect on the morphology, adhesion, proliferation, cell cycle and ultrastructure of bladder cancer cells using 2D and 3D models. Their observations strongly encourage future studies to identify the molecules that induce the detrimental effects in cancer cells and their mechanism of action.

Odet et al. address the growing interest in human amniotic membrane in oral surgery, and they discuss in detail suitable procedures for it's use in soft and hard tissue reconstruction in the oral cavity. This serves as a useful reference to guide new ideas for the development of innovative protective covering, suturing or handling devices in oral surgery. In addition, Etchebarne et al. present a systematic review of the literature to assess the benefit of using the amniotic membrane and derived products for bone regeneration. They underline how the amniotic membrane is a promising alternative to the commercially available membranes used for guided bone regeneration, and how cells isolated from the amniotic membrane can be combined with scaffolds for tissue engineering strategies applied to bone healing.

Other contributions focus on potential strategies to enhance perinatal cell therapeutic properties. For example, Zentelyte et al. investigated the effects of short term treatments of small molecules to improve the stem cell properties and differentiation capability of amniotic fluid stem cells. The results of this study provide valuable insights for the potential use of short term small molecule treatments to improve stem cell characteristics and boost differentiation potential of amniotic fluid stem cells. Citeroni et al. propose a new approach able to promote teno-differentiation for veterinary and medical purposes by evaluating the tenoinductive properties of the secretome derived from ovine tendon fetal tissue on ovine amniotic epithelial cells. They also discuss protocols for the production and storage of the optimal tendon-derived secretome.

Finally, two case studies present promising data for the use of lyophilized amniotic membrane in patients with chronic wounds. Schmeidova et al. performed a multicentre observational study on the use of a lyophilized amniotic membrane for the treatment of chronic wounds (various aetiologies). Out of 16 enrolled patients, 8 patients were completely healed, 6 patients demonstrated significantly reduced ulcer size and 2 subjects did not respond to therapy. This study demonstrates an effective alternative to the standard of chronic wounds care and confirms a significant effect of the application of lyophilized amntioic membrane for chronic wound management as a new standard of care. Lipový et al. present a case study using a lyophilized amniotic membrane for accelerating wound healing in a patient with Toxic epidermal necrolysis (TEN), a rare life-threatening disease that mainly affects the skin and mucous membranes, resulting from a toxic delayed-type hypersensitivity reaction type IV. Lyophilized amniotic membrane demonstrated excellent biocompatibility and accelerated epithelialization and the current therapy of patients with TEN with better outcomes and patient recovery.

Last, but not least, Papait et al. address a topic of recent and urgent interest, that is the COVID-19 pandemic. They provide and extensive overview of the characteristics of perinatal cells with a particular focus on the beneficial effects that they could have in patients with COVID-19, and more specifically for their potential use in the treatment of ARDS and sepsis.

This topic issue will be followed by a second volume that will further contribute to the SPRINT COST Action aimed to understand the mechanisms and therapeutic actions of perinatal derivatives, to critically discuss basic research data that can be useful for designing clinical trials, and to identify research gaps so as to guide future research on perinatal derivatives and streamline translation to the clinic.

Engraftment potential of human amnion and chorion cells derived from term placenta

Human placenta-derived cells have mesenchymal stem/ progenitor cell potential

Isolation and characterization of mesenchymal progenitor cells from chorionic villi of human placenta

Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta

Isolation and characterization of mesenchymal cells from human fetal membranes

Wharton's jelly-derived cells are a primitive stromal cell population

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.Frontiers in Bioengineering and Biotechnology | www.frontiersin.orgAugust 2021 | Volume 9 | Article 741156